Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Memantine augmentation for refractory obsessive-compulsive disorder.

Massimo Pasquini1, Massimo Biondi

  • 1Department of Psychiatric Science and Psychological Medicine, University La Sapienza of Rome, Italy. maxpasquini@tiscalinet.it

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|May 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demoralization in patients with obsessive-compulsive disorder: results from an exploratory cross-sectional report.

Annals of general psychiatry·2026
Same author

The final appointment: risk factors and prevention of femicide.

Rivista di psichiatria·2026
Same author

Sweet taste hedonic response in anorexia nervosa: connections with nutritional status and psychopathology.

Eating and weight disorders : EWD·2026
Same author

Psychopathological Concomitants and Motivations Related to Misuse of Non-Steroidal Anti-Inflammatory Drugs and Paracetamol.

Human psychopharmacology·2026
Same author

Childhood Maltreatment and Suicide Risk in Migrant Psychiatric Inpatients: The Mediating Role of Depressive Symptoms.

The International journal of social psychiatry·2026
Same author

Unaware and unrestrained: binge-eating behavior in epileptic absence seizures.

Eating and weight disorders : EWD·2026
Same journal

The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Beyond gray matter: unveiling the critical role of white matter in Alzheimer's disease.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Chronic pain and stress: Transdiagnostic meta-analytic evidence of convergent network signature with PTSD.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same journal

Association of rs4705342 T > C polymorphism in the promoter of miR-143/145 with cognitive impairment in adolescents with depressive disorder: A case-control study.

Progress in neuro-psychopharmacology & biological psychiatry·2026
See all related articles

Memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, was tested as an augmentation therapy for refractory obsessive-compulsive disorder (OCD). Results varied, suggesting potential subtype differences in OCD treatment response.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • The glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) remains largely untested.
  • Memantine, an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, is a potential therapeutic agent for neurological and psychiatric conditions.

Observation:

  • Two cases of refractory OCD were treated with memantine augmentation at 15 mg/day.
  • One patient showed no benefit, while the other experienced immediate and substantial improvement.

Findings:

  • Treatment outcomes with memantine varied significantly between the two refractory OCD cases.
  • These contrasting results suggest the existence of distinct OCD subtypes influencing treatment response.

Implications:

Related Experiment Videos

  • Further research into OCD subtypes may elucidate differential responses to NMDA receptor antagonists like memantine.
  • Targeting specific glutamatergic pathways could lead to more personalized and effective OCD treatments.
  • Investigating agents that enhance memory for actions might reduce orbitofrontal cortex activation in certain OCD subtypes.